
    
      The purpose of this study was to evaluate the tolerability, safety pharmacokinetics and
      pharmacodynamic (biomarkers) of ASC41 tables in a randomized, double-blind,
      placebo-controlled single- and multiple-dose phase I clinical trial in healthy subjects the
      study. The effects of ASC41 on LDL-C and other lipid parameters (TG, TC, HDL-C, etc.) will be
      observed after repeated administration of ASC41 in healthy subjects.
    
  